清胰汤联合生长抑素治疗重症急性胰腺炎的疗效评价

A Meta-analysis:Qingyi Decoction Combined with Somatostatin on Acute Pancreatitis

目的系统评价清胰汤联合生长抑素治疗重症急性胰腺炎的有效性和安全性。方法计算机检索Cochrane library、Pub Med、中国生物医学文献数据库、中国知网、万方数据库、维普数据库建库至2018年1月的中药清胰汤联合生长抑素治疗重症急性胰腺炎(SAP)的中英文随机对照试验(RCT)。评价文章质量及偏倚风险,采用Rev Man5.3软件进行Meta分析。结果共15项RCT,1225名患者。Meta分析结果显示:实验组在死亡率[RR=0.48,95%CI(0.30,0.77)]、治愈率[RR=1.42,95%CI(1.20,1.68)]、并发症发生率[RR=0.58,95%CI(0.35,0.97)]、腹胀缓解时间[MD=-2.21,95%CI(-2.63,-1.79)]、腹痛缓解恢复时间[MD=-2.06,95%CI(-2.54,-1.58)]、住院时间[MD=-5.78,95%CI(-6.57,-4.99)]、血清淀粉酶恢复时间[MD=-2.50,95%CI(-3.17,-1.83)]和APACHEⅡ评分改善[MD=-3.09,95%CI(-4.52,-1.65)]方面优于对照组,且差异具有统计学意义。结论清胰汤联合生长抑素治疗SAP能够更好的缓解患者不良症状以及改善疾病进程。

Objective： To evaluate the efficacy and safety of Qingyi Decoction combined with somatostatin on severe acute pancreatitis. Methods： A computerized search was performed to collect all the randomized controlled trials（RCT） about Qingyi Decoction combined with somatostatin on severe acute pancreatitis in Cochrane library,Pub Med,CBM,CNKI,Wanfang database. After evaluating the quality and the risk of bias of the article,Meta-analysis was implement with Rev Man 5.3 software. Results： 15 RCTs were performed and 1225 patients were included in this study. The results of the Meta-analysis showed in the test group,the rate of the mortality [RR =0.48,95%CI（0.30,0.77）],cure rate [RR =1.42,95% CI（1.20,1.68）],incidence rate of complications [RR =0.58,95% CI（0.35,0.97）],recovery time of abdominal distension [MD =-2.21,95% CI（-2.63,-1.79）],recovery time of abdominal pain [MD=-2.06,95%CI（-2.54,-1.58）],hospitalization days [MD=-5.78,95%CI（-6.57,-4.99）],recovery time of serum amylase [MD=-2.50,95%CI（-3.17,-1.83）],APACHEⅡ score [MD=-3.09,95%CI（-4.52,-1.65）],all data above was superior to that of the control group,with significant difference. Conclusion： Qingyi Decoction combined with somatostatin on severe acute pancreatitis can better relieve patients′bad symptoms and improve the course of disease.